Incyte’s Phase II Study for Opzelura Returns Promising Results in Adult Patients
March 11th 2024The company’s twice-daily, branded ruxolitinib cream 1.5% presents a significant reduction in abscess and inflammatory nodule (AN) count for the treatment of Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa.
Examining the Impact of the COVID-19 Pandemic on Patient Portal Use
March 1st 2024A JAMA Network Open study dives into how the utilization of a digital patient portal changed during the COVID-19 pandemic, while also exploring ways that multimorbidity and socioeconomic disparities affected those statistics.
Streamlining for Safety: Navigating Changes and Trends in the Pharmaceutical Supply Chain Post-DSCSA
March 1st 2024With its aims to protect healthcare consumers against the dangers of counterfeit, contaminated, stolen or otherwise harmful drugs, the DSCSA represents a significant step forward in securing the pharmaceutical supply chain.
Cencora's Corey Ford Discusses the Future of the Inflation Reduction Act
February 29th 2024In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement & Policy Insights, Cencora, offers his thoughts on where the Inflation Reduction Act will be five to 10 years from now.
Cencora VP of Reimbursement & Policy Insights Discusses Implications of the Inflation Reduction Act
February 28th 2024In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement, Policy Insights, Cencora, provides a look at his recent webinar focused on the implications of the Inflation Reduction Act.